CureVac N.V. (NASDAQ:CVAC) released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate.
The study is part of a collaboration with GSK Plc (NYSE:GSK).
The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate.
It was designed for broad antigen coverage, encoding antigens matched to all four WHO-recommended flu strains.
Results show that the multivalent vaccine candidate using CureVac’s proprietary second-generation mRNA backbone boosted antibody titers against all encoded flu strains and across all ...